



HF in patients with T2D



People with **T2D** have a 2-fold greater risk of **HF** versus those without **T2D**¹




Up to 3 in 10 people with T2D have HF2

Monitor patients with T2D to reduce HF risk³



Assess CV risk factors at least annually for prevention and management of ASCVD and HF



Dyslipidemia

Obesity/overweight

Hypertension

Smoking



Chronic kidney disease Family history of premature coronary disease

Presence of albuminuria



Management of patients with T2D and HF3



Lifestyle modifications, including exercise and balanced caloric intake



Lipid management



management



Glycemic



Standard treatment, (eg, β-blockers, mineralocorticoid inhibitor, and consideration of ACEIs and ARBs)

Select appropriate glucose-lowering therapies for patients with T2D and HF³⁻⁵



M METFORMIN

- First-line therapy for T2D, including those with HF
- Reduces mortality and CV morbidity in patients with diabetes, with or without HF⁶
- Continue for glucose-lowering as long as it is tolerated and not contraindicated
- Avoid in unstable/hospitalized with HF
- Avoid if eGFR <30 mL/min/1.73 m²

S SGLT2 INHIBITORS

- Consider independently of baseline or target A1c to reduce risk of HHF
- Prefer agent with evidence of reducing HF risk
- Canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin reduce risk of HHF 7,8
- Canagliflozin and empagliflozin reduce risk of MACE; empagliflozin reduces risk of CV death³
- Consider SGLT2 inhibitor with proven benefit in patients with T2D and established HFrEF to reduce risk of worsening HF and CV death^{9,10}; may be a class effect⁴
- Avoid if eGFR <45 mL/min/1.73 m² (<30 for canagliflozin and ertugliflozin)

© GLP-1 RAs

- Add GLP-1 RA with proven CVD benefit
 - IF SGLT2 inhibitor not tolerated or contraindicated, or if eGFR less than adequate
 - IN ADDITION to SGLT2 inhibitor if A1c above target
- → No significant effect on HF risk^{11,12}
- wodestrip Liraglutide, semaglutide, and dulaglutide reduce risk of MACE, particularly in patients with CVD 11,12
- → Reduce all-cause mortality^{11,12}

OTHER AGENTS

- Consider if A1c above target
- DPP-4 inhibitor (not saxagliptin) in the setting of HF (if not on GLP-1 RA)
- Basal insulin
- Sulfonylurea
- TAVOID thiazolidinediones

- 1. Komanduri S, et al. *J Community Hosp Intern Med Perspect*. 2017;7:15-20.
 2. Seferovic PM, et al. *Eur J Heart Fail*. 2018;20:853-872.
 3. American Diabetes Association. *Diabetes Care*. 2020;43:S111-S134.
 4. American Diabetes Association. *Diabetes Care*. 2020;43:S111-S134.
 5. American Diabetes Association. *Diabetes Care*. 2020;43:S98-S110.
 6. Maack C, et al. *Eur Heart J*. 2018;39:4243-4254.
 6. Maack C, et al. *Eur Heart J*. 2018;39:4243-4254.
 7. Zelniker TA, et al. *Lancet*. 2019;393:31-39.
 8. Cannon CP, et al. *N Engl J Med*. 2020;383:1425-1435.
 9. McMurray JJV, et al. *N Engl J Med*. 2019;381:1995-2008.
 10. Packer M, et al. *N Engl J Med*. 2020;383:1413-1424.
 11. Giugliano D, et al. *Diabetes Obes Metab*. 2019;21:2576-2580.
 12. Giugliano D, et al. *Diabetes Obes Metab*. 2019;21:1081-1087.

- ADA, American Diabetes Association; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure;